KLRA

Kailera Therapeutics, Inc. NASDAQ Listed Apr 17, 2026

Healthcare ·Biotechnology ·US · kailera.com

$16.94

-0.65% vs $17.05

Mkt Cap $2.2B

52w Low $16.39 4.6% of range 52w High $28.23

50d MA $20.13 200d MA $21.13

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity —

ROE —

P/FCF —

RSI (14) 25.80

ATR (14) $1.22

Beta 0.00

50d MA $20.13

200d MA $21.13

Avg Volume 951.6K

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.

SIC Code

2834

CIK (SEC)

2096997

Phone

(781) 317-0290

180 Third Avenue, 4th Floor · Waltham, MA 02451 · US

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 12	Evercore ISI	Initiates	Outperform	—	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%
May 12	Jefferies	Initiates	Buy	$48	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%
May 12	JP Morgan	Initiates	Overweight	$30	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%
May 12	Leerink Partners	Initiates	Outperform	$36	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%
May 12	TD Cowen	Initiates	Buy	$57	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%
May 12	William Blair	Initiates	Outperform	—	$22.93	$23.41	+2.1%	-2.7%	-5.3%	+1.8%	-2.1%	-7.1%

Institutional (13F) — Top 0 All ↗

No 13F holders found.

Mutual Funds / ETFs (N-PORT) — Top 4 All ↗

#	Fund	Shares	Value	Period
1	Select Biotechnology Portfolio	619,399	$14M	May 2026
2	BlackRock Health Sciences Opportunities Portfolio	464,174	$11M	May 2026
3	Strategic Advisers U.S. Total Stock Fund	82,700	$2M	May 2026
4	Select Pharmaceuticals Portfolio	9,000	$206K	May 2026

Data updated apr 25, 2026 5:36pm · Source: financialmodelingprep.com